MedPath

Rivastigmine treatment for electroconvulsive therapy- induced confusion in elderly depressed patients

Phase 1
Conditions
Interictal delirium during electric convulsive therapy- course
Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]
Registration Number
EUCTR2014-003385-24-NL
Lead Sponsor
GGZ inGeest, parner VUmc
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Authorised-recruitment may be ongoing or finished
Sex
All
Target Recruitment
38
Inclusion Criteria

- Patient is admited at the in-wards of one of the participating psychiatric hospitals
- Patients fulfilling the Composite International Diagnostic Interview (CIDI) criteria of a Major Depressive Episode (not necessarily in the context of a Major Depressive Disorder only)
- Patient is indicated for ECT-treatment.
- Patient or legal representitive is able to give informed consent
- Occurence of an interictal delirium is assessed by the Confusion Assessment method (CAM) and/ or 4 pts drop Mini Mental State Examination score (MMSE)
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 38
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 38

Exclusion Criteria

- Patients not meeting the inclusion criteria
- Patient has a comorbid medical condition that is a contraindication for ECT according to the prevailing Dutch ECT-guidelines
- Current use of rivastigmine or an other cholinesterase inhibitor
- Known intolerance of rivastigmine or an other cholinesterase inhibitor
- Bradycardia or AV conduction disorder at baseline ECG (first degree AV block exluded)
- switch from right unilateral electrodeplacement (RUL) to bilateral electrodeplacement (BL) during trial

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath